Over the last 12 months, Immunome insiders reported 1 buy totaling $204K and 8 sales totaling $12.7M across SEC Form 4 filings. 78% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Horn KinneyCHIEF BUSINESS OFFICER · O | ▼ Sale | 90,616 | $25.09 | $2.3M | -100% | plan |
| Jul 7, 2026 | Horn KinneyCHIEF BUSINESS OFFICER · O | ▼ Sale | 1,092 | $25 | $27K | -100% | plan |
| Jul 7, 2026 | Barchas IsaacD | ▼ Sale | 100,000 | $24.13 | $2.4M | -48% | plan · 2 tranches · indirect |
| Jul 2, 2026 | Barchas IsaacD | ▼ Sale | 201,050 | $21.85 | $4.4M | -49.1% | plan · 3 tranches · indirect |
| Jul 2, 2026 | Lechleider RobertChief Medical Officer · O | ▼ Sale | 55,000 | $22.62 | $1.2M | -77.7% | plan · 3 tranches |
| Jun 25, 2026 | Lechleider RobertChief Medical Officer · O | ▼ Sale | 55,000 | $19.85 | $1.1M | -77.7% | plan · 2 tranches |
| Jun 15, 2026 | Rosett MaxChief Financial Officer · O | ▼ Sale | 60,000 | $18.23 | $1.1M | -52.6% | plan |
| Jun 5, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 10,500 | $19.45 | $204K | +31.9% | 3 tranches |
| Jun 5, 2026 | BIENAIME JEAN JACQUESD | ▼ Sale | 10,500 | $19.41 | $204K | -24.2% | 2 tranches |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $IMNM feed.